Institutional Investor Atlas Venture Files Intent to Sell $1.37M in Dyne Therapeutics Shares
DYN has more than doubled off its 52-week low of $8.06.
Summary
Atlas Venture Fund XI, LP intends to sell $1.37 million in Dyne Therapeutics shares, continuing a pattern of significant distribution by the institutional investor.
Key Events · Ownership and Investor Activity · DYN
-
Proposed Share Sale
Atlas Venture Fund XI, LP intends to sell 72,310 shares of common stock, valued at approximately $1,366,659.00.
-
Ongoing Institutional Distribution
This filing continues a pattern of significant share sales by Atlas Venture entities, which have sold over $17 million in Dyne Therapeutics stock in the past week.
-
Shareholder Relationship
The filer, Atlas Venture Fund XI, LP, is identified as a shareholder of Dyne Therapeutics.
Analysis · DYN · Life Sciences
Atlas Venture Fund XI, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $1.37 million worth of Dyne Therapeutics common stock. This filing is part of a broader, ongoing distribution by Atlas Venture, which has been consistently selling shares over the past week, totaling over $17 million. While the individual transaction is notable, the continuous selling by a major institutional investor could create an overhang on the stock, signaling a reduction in their stake.
At the time of this filing, DYN was trading at $18.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.